Why Coherus BioSciences Stock Jumped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) are up 19.7% as of 3:20 p.m. ET Thursday after the U.S. Food and Drug Administration (FDA) approved Udenyca OnBody, the company's on-body injection system that can be taken to prevent infection in chemotherapy patients.
Recall shares of Coherus fell under pressure back in September after the FDA issued a complete response letter (CRL) for its Udenyca OnBody biologics license application. Coherus was quick to point out the agency did not raise concerns about Undenyca's labeling, efficacy, or safety, but was rather concerned over potential issues at a third-party manufacturing site for the system.
Sure enough, Coherus resubmitted that application in October following the completion and satisfactory resolution of the FDA's review. And during the company's subsequent earnings conference call last month, management told investors it expected the potential approval to arrive either late this year or by early 2024. From an investor's standpoint, it's obviously encouraging that Coherus received its formal approval on the earlier end of that range.
Source Fool.com
Coherus Bioscien. Stock
Based on 2 Buy predictions and 2 Sell predictions the sentiment towards Coherus Bioscien. is rather balanced.
As a result the target price of 3 € shows a positive potential of 42.52% compared to the current price of 2.11 € for Coherus Bioscien..
